Washington D.C., Aug. 12 (ANI
): A new University of Pittsburgh School of Medicine study says that identifying and treating metabolic deficiencies
in patients with treatment-resistant depression can improve symptoms and in some cases even lead to remission.
"What's really promising about these new findings is that they indicate that there may be physiological mechanisms underlying depression that we can use to improve the quality of life in patients with this disabling illness," said researcher David Lewis.
Major depressive disorder, also referred to simply as depression, affects nearly 15 million American adults and is one of the most common mental disorders.
Unfortunately, at least 15 percent of patients don't find relief from conventional treatments such as antidepressant medications and psychotherapy, explained lead study investigator Lisa Pan. Depression
also is the cause of more than two-thirds of suicides that occur annually.
The groundwork for the current study was laid five years ago when Pan with an associate treated a teen with a history of suicide attempts and long-standing depression.
"Over a period of years, we tried every treatment available to help this patient, and yet he still found no relief from his depression symptoms," she explained.
After receiving an analogue of biopterin to correct the deficiency, the patient's depression symptoms largely disappeared and today he is a thriving college student.
The success prompted the researchers to examine other young adults with depression who were not responding to treatment, explained Pan.
In the published trial, the researchers looked for metabolic abnormalities in 33 adolescents and young adults with treatment-resistant depression and 16 controls.
Although the specific metabolites affected differed among patients, the research
ers found that 64 percent of the patients had a deficiency in neurotransmitter metabolism, compared with none of the controls.
In almost all of these patients, treating the underlying deficiency improved their depression symptoms, and some patients even experienced complete remission.
In addition, the further along the patients progress in the treatment
, the better they are getting, she added.
The study has been published in American Journal of Psychiatry. (ANI